Efficacy responses with tildrakizumab in moderate-to-severe chronic plaque psoriasis patients with previous exposure to apremilast: Results of a pooled analysis of reSURFACE 1 and reSURFACE 2

Efficacy responses with tildrakizumab in moderate-to-severe chronic plaque psoriasis patients with previous exposure to apremilast: Results of a pooled analysis of reSURFACE 1 and reSURFACE 2 Meeting Abstract

publication date

September 1, 2018

webpage

Web of Science

published in

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Journal

start page

AB125

end page

AB125

volume

79

issue

3